BiotechTube
Ambrosia Biosciences

Ambrosia Biosciences

San Diego, United States· Est.
ambrosiabiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17M

Overview

Ambrosia Biosciences is a preclinical-stage drug discovery company targeting metabolic diseases, particularly obesity, with orally bioavailable small molecules. The company's core strategy is to apply an integrated platform combining cryo-EM structural biology, biophysics, and AI-powered design to tackle Class B GPCRs, a validated but underexploited target class. With a seasoned leadership team and a pipeline centered on GLP-1R, GIPR, and amylin receptor modulators, Ambrosia aims to develop best-in-class oral therapies that could offer significant advantages over current injectable peptide drugs. The company is currently pre-revenue and privately held.

ObesityMetabolic Disorders

Technology Platform

Integrated structure-based drug discovery platform combining cryo-EM-enabled structural biology, biophysical binding assays, and AI-powered molecular design to target Class B GPCRs for oral small molecule drug development.

Funding History

2
Total raised:$17M
Series A$15M
Seed$2M

Opportunities

The global obesity drug market, validated by injectable GLP-1 drugs, presents a multi-billion dollar opportunity.
A successful oral small molecule therapy could capture significant market share due to patient preference for pills over injections, potentially improving adherence.
Furthermore, developing novel combinations (e.g., GLP-1R agonist + GIPR antagonist) targets the next wave of therapy seeking greater efficacy.

Risk Factors

The primary risk is the high scientific difficulty of developing effective oral small molecules for Class B GPCR targets, a historically challenging endeavor.
The company also faces intense competition from large pharma and well-funded biotechs in the obesity space.
As a pre-revenue, private company, it carries significant financial risk and dependence on future fundraising.

Competitive Landscape

Ambrosia operates in the highly competitive obesity therapeutics arena, competing directly with giants like Novo Nordisk and Eli Lilly, who have established injectable and are developing oral therapies. It also competes with other biotechs (e.g., Pfizer, Structure Therapeutics) pursuing oral small molecule GLP-1R agonists. Differentiation will require demonstrating a superior clinical profile.

More companies in Small Molecule Drugs →More companies in United States →